查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1989037

神經免疫療法市場預測至2034年—按治療方法類型、適應症、給藥途徑、技術、最終用戶、分銷管道和地區分類的全球分析

Neuroimmune Therapy Market Forecasts to 2034 - Global Analysis By Therapy Type, Indication, Route of Administration, Technology, End User, Distribution Channel, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球神經免疫療法市場規模將達到 282 億美元，並在預測期內以 10.6% 的複合年成長率成長，到 2034 年將達到 633 億美元。

神經免疫療法是指透過針對神經系統和免疫系統的交叉點，來治療由異常免疫活動引起或加劇的神經系統疾病的醫療手段。這些治療方法包括單株抗體、自體免疫、細胞激素抑制劑、細胞療法和基因療法，旨在調節神經發炎並恢復免疫平衡，用於治療多發性硬化症、自體免疫性腦炎和神經退化性疾病等疾病。透過精準調節大腦和神經系統中的免疫通路，神經免疫療法為過去難以治療或控制不佳的神經系統疾病患者帶來了新的希望。

自體免疫神經系統疾病盛行率增加

隨著人口老化和診斷能力的提高，包括多發性硬化症、視神經脊髓炎、自體免疫腦炎和神經發炎性阿茲海默症在內的神經免疫疾病的全球負擔日益加重。對神經損傷免疫機制的深入了解，為靶向生技藥品、免疫調節劑和細胞療法等新的治療方案開闢了道路。患者數量的不斷成長、巨大的未滿足醫療需求以及神經免疫學領域的快速發展，正推動著製藥企業對相關藥物的研發和商業化進行大量投資。

藥物研發和臨床試驗成本高昂

開發新型神經免疫療法，特別是針對中樞神經系統的生物製藥（例如單株抗體和細胞療法），需要巨額的前期投資，用於標靶檢驗、臨床前試驗、多階段臨床試驗以及生產基礎設施建設。由於難以客觀評估療效以及臨床試驗設計的複雜性，在神經系統疾病適應症中確立藥物的安全性和有效性極具挑戰性，這進一步增加了研發成本和時間。神經系統藥物研發的高失敗率帶來了巨大的財務風險。

不斷擴充的生物神經治療候選藥物研發管線

神經免疫療法研發管線是整個生物製藥產業中最活躍、最具創新性的領域之一，眾多新型候選療法正處於後期臨床開發階段，針對多發性硬化症、阿茲海默症相關的神經發炎以及罕見的自體免疫神經系統疾病。抗體工程、CAR-T細胞技術、反義寡核苷酸和基因治療平台的進步正在拓展可治療的神經免疫標靶範圍。隨著有前景的候選藥物逐步獲得監管部門的核准，這項豐富的研發管線蘊藏著巨大的商業性機會。

新型生物製藥的複雜核准流程

針對中樞神經系統的新型生物製藥的監管核准流程是藥物研發中最嚴格、最難預測的流程之一。監管機構要求提供大量臨床證據，證明其在神經系統疾病適應症的安全性和有效性，通常需要進行大型、長期的臨床試驗，並設定複雜的終點指標。此外，生產符合監管核准所需的品質和一致性標準的生物製藥也需要付出更高的成本和更大的複雜性。

新冠疫情的影響：

新冠疫情對神經免疫療法市場產生了重大影響，凸顯了免疫系統與神經系統相互作用在健康結果中的關鍵作用。新冠感染疾病和免疫失調的研究不斷深入，加速了人們對神經免疫療法的興趣。製藥公司和研究機構投入大量資金開發針對併發症和免疫相關神經系統疾病的治療方法。儘管監管限制導致臨床試驗延期，但從長遠來看，其影響是積極的，人們對神經免疫療法的認知不斷提高，推動了創新，並使其成為現代醫療保健的重要組成部分。

在預測期內，單株抗體領域預計將佔據最大佔有率。

單株抗體療法在神經免疫治療市場中佔最大佔有率。這些高度特異性的生物製劑透過選擇性靶向病理性免疫通路，徹底改變了多發性硬化症、視神經脊髓炎和其他自體免疫神經系統疾病的治療。其已證實的臨床療效、成熟的生產流程以及不斷增加的核准產品，造就了一個規模龐大且商業性佔據主導地位的細分市場。隨著臨床試驗不斷探索新的神經免疫適應症，單株抗體療法的潛在市場正在進一步擴大。

預計在預測期內，多發性硬化症細分市場將呈現最高的複合年成長率。

在預測期內，多發性硬化症 (MS) 細分市場預計將在神經免疫療法市場中實現最高的複合年成長率 (CAGR)。多發性硬化症 (MS) 是全球最常見嚴重的神經免疫疾病，確診患者人數不斷增加，對更有效的治療方法的需求也遠未得到滿足。下一代疾病修正治療的快速發展、生物製藥治療選擇的擴展以及對 MS 患者精準神經免疫學投入的增加，正在推動該細分市場在預測期內保持卓越的複合年成長率。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這得益於其先進的醫療保健基礎設施、強大的製藥公司網路以及對神經免疫學研究的大力投入。該地區受益於政府的支持、自體免疫疾病和神經系統疾病的高發生率以及生物技術公司與學術機構之間的合作。此外，創新治療方法的早期應用和健全的法規結構確保北美繼續保持神經免疫療法開發和商業化的領先地位。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於醫療保健支出不斷成長、人們對神經系統和免疫相關疾病的認知日益提高以及藥物研發能力的不斷增強。中國、印度和日本等國家正大力投資生技和先進治療方法，並得到政府推動醫療創新措施的支持。神經免疫疾病盛行率的不斷上升以及龐大的患者群體正在推動市場需求。科技的快速應用和扶持政策使亞太地區成為該市場成長最快的地區。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要企業進行SWOT分析（最多3家公司）
  • 區域細分
    • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對主要企業進行基準分析。

目錄

第1章：執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要企業市佔率分析
  • 產品基準評效和效能比較

第5章 全球神經免疫療法市場：依治療方法分類

  • 單株抗體
  • 免疫調節劑
  • 細胞激素抑制劑
  • 細胞療法
  • 基因治療
  • 小分子藥物
  • 聯合治療

第6章：全球神經免疫療法市場：依適應症分類

  • 多發性硬化症
  • 視神經脊髓炎
  • 自體免疫腦炎
  • 重症肌無力
  • 阿茲海默症
  • 帕金森氏症

第7章 全球神經免疫療法市場：依給藥途徑分類

  • 靜脈
  • 皮下
  • 口服
  • 鞘內腔

第8章 全球神經免疫療法市場：依技術分類

  • 生物製藥開發
  • 重組DNA技術
  • 細胞工程
  • 精準醫療平台

第9章 全球神經免疫療法市場：依最終用戶分類

  • 醫院
  • 專科診所
  • 研究機構
  • 門診手術中心

第10章 全球神經免疫療法市場：依分銷管道分類

  • 醫院藥房
  • 零售藥房
  • 網路藥房

第11章 全球神經免疫療法市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第12章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第13章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第14章：公司簡介

  • Roche Holding AG
  • Novartis AG
  • Pfizer Inc.
  • Johnson & Johnson
  • Bristol-Myers Squibb Company
  • Biogen Inc.
  • Merck & Co., Inc.
  • Eli Lilly and Company
  • Sanofi SA
  • AbbVie Inc.
  • GlaxoSmithKline plc
  • Amgen Inc.
  • UCB SA
  • Takeda Pharmaceutical Company Limited
  • AstraZeneca plc
  • Regeneron Pharmaceuticals, Inc.
  • Bayer AG
  • Teva Pharmaceutical Industries Ltd.
Product Code: SMRC34326

According to Stratistics MRC, the Global Neuroimmune Therapy Market is accounted for $28.2 billion in 2026 and is expected to reach $63.3 billion by 2034 growing at a CAGR of 10.6% during the forecast period. Neuroimmune therapy refers to medical treatments that target the intersection of the nervous system and immune system to address neurological diseases driven or worsened by abnormal immune activity. These therapies include monoclonal antibodies, immunomodulators, cytokine inhibitors, cell-based treatments, and gene therapies designed to regulate neuroinflammation and restore immune balance in conditions such as multiple sclerosis, autoimmune encephalitis, and neurodegenerative diseases. By precisely modulating immune pathways in the brain and nervous system, neuroimmune therapies offer new hope for patients with previously untreatable or poorly managed neurological conditions.

Market Dynamics:

Driver:

Rising prevalence of autoimmune neurological diseases

The global burden of neuroimmune diseases, including multiple sclerosis, neuromyelitis optica, autoimmune encephalitis, and neuroinflammatory forms of Alzheimer's disease, is growing as populations age and diagnostic capabilities improve. Advances in understanding the immunological mechanisms underlying neurological damage have opened new therapeutic windows that targeted biologics, immunomodulators, and cell-based therapies can exploit. The combination of growing patient populations, significant unmet medical need, and rapidly maturing neuroimmunology science is driving substantial pharmaceutical investment in developing and commercializing.

Restraint:

High drug development and clinical trial costs

Developing novel neuroimmune therapies, particularly biologic agents such as monoclonal antibodies and cell-based therapies targeting the central nervous system, requires enormous upfront investment in target validation, preclinical studies, multi-phase clinical trials, and manufacturing infrastructure development. The complexity of demonstrating safety and efficacy in neurological indications, where outcomes are difficult to measure objectively and clinical trial designs are complex, further inflates development costs and timelines. High failure rates in neurology drug development create substantial financial risk.

Opportunity:

Growing pipeline of biologic neurotherapy candidates

The neuroimmune therapy pipeline is among the most active and innovative segments of the broader biopharmaceutical industry, with numerous novel therapeutic candidates in advanced clinical development targeting multiple sclerosis, Alzheimer's neuroinflammation, and rare autoimmune neurological disorders. Advances in antibody engineering, CAR-T cell technology, antisense oligonucleotides, and gene therapy platforms are expanding the range of neuroimmune targets that can be addressed therapeutically. This rich pipeline represents a substantial commercial opportunity as successful candidates advance toward regulatory.

Threat:

Complex regulatory approval for novel biologics

The regulatory pathway for novel biologic therapies targeting the central nervous system is among the most demanding and unpredictable in pharmaceutical development. Regulatory agencies require extensive clinical evidence of safety and efficacy in neurological indications, often including large and long-duration trials with complex outcome measures. Manufacturing biologics to quality and consistency standards required for regulatory approval adds further complexity and cost.

Covid-19 Impact:

The Covid-19 pandemic significantly influenced the Neuroimmune Therapy Market, as the virus highlighted the critical role of immune and neurological interactions in health outcomes. Increased research into post-Covid neurological complications and immune dysregulation accelerated interest in neuroimmune therapies. Pharmaceutical companies and research institutions invested heavily in developing treatments targeting inflammation and immune-related neurological disorders. While clinical trials faced delays due to restrictions, the long-term impact was positive, with heightened awareness driving innovation and positioning neuroimmune therapies as vital in modern healthcare.

The monoclonal antibodies segment is expected to be the largest during the forecast period

The monoclonal antibodies segment holds the largest share in the neuroimmune therapy market. These highly specific biologics have transformed treatment for multiple sclerosis, neuromyelitis optica, and other autoimmune neurological conditions by selectively targeting pathological immune pathways. Their proven clinical efficacy, established manufacturing processes, and growing number of approved products create a large and commercially dominant segment. Continued clinical trials exploring new neuroimmune indications further expand the addressable market for monoclonal antibody therapies.

The multiple sclerosis segment is expected to have the highest CAGR during the forecast period

The multiple sclerosis segment is expected to register the highest CAGR in the neuroimmune therapy market over the forecast period. MS remains the most prevalent serious neuroimmune disease globally, with a growing diagnosed patient population and strong unmet medical need for more effective therapies. Rapid development of next-generation disease-modifying therapies, expanding biological treatment options, and increasing investment in precision neuroimmune medicine for MS patients are driving the segment's exceptional compound annual growth rate across the forecast period.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share owing to its advanced healthcare infrastructure, strong presence of pharmaceutical companies, and robust investment in neuroimmune research. The region benefits from supportive government initiatives, high prevalence of autoimmune and neurological disorders, and collaborations between biotech firms and academic institutions. Additionally, early adoption of innovative therapies and strong regulatory frameworks ensure North America remains the leading hub for neuroimmune therapy development and commercialization.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to rising healthcare expenditure, growing awareness of neurological and immune-related conditions, and expanding pharmaceutical research capabilities. Countries such as China, India, and Japan are investing heavily in biotechnology and advanced therapies, supported by government initiatives promoting healthcare innovation. Increasing prevalence of neuroimmune disorders, coupled with a large patient population, drives demand. With rapid technological adoption and supportive policies, Asia Pacific emerges as the fastest-growing region in this market.

Key players in the market

Some of the key players in Neuroimmune Therapy Market include Roche Holding AG, Novartis AG, Pfizer Inc., Johnson & Johnson, Bristol-Myers Squibb Company, Biogen Inc., Merck & Co., Inc., Eli Lilly and Company, Sanofi S.A., AbbVie Inc., GlaxoSmithKline plc, Amgen Inc., UCB S.A., Takeda Pharmaceutical Company Limited, AstraZeneca plc, Regeneron Pharmaceuticals, Inc., Bayer AG, and Teva Pharmaceutical Industries Ltd.

Key Developments:

In February 2026, Pfizer emphasized AI-enabled neuroimmune therapy platforms, projecting improved treatment efficiency and patient monitoring. At global medical summits, the company showcased demand response automation for neurological care, highlighting sustainability, personalization, and resilience in addressing complex immune-related health challenges.

In January 2026, Roche advanced neuroimmune therapy research, unveiling AI-driven analytics for personalized treatment pathways. The company emphasized demand-responsive clinical solutions, integrating predictive models to optimize resilience, efficiency, and patient outcomes across neurological and autoimmune conditions worldwide.

In January 2026, Novartis introduced innovative neuroimmune therapies, leveraging digital twins and machine learning for adaptive treatment. The initiative focused on demand-responsive drug development, enhancing sustainability, efficiency, and resilience while supporting flexible deployment across hospitals, clinics, and global healthcare ecosystems.

Therapy Types Covered:

  • Monoclonal Antibodies
  • Immunomodulators
  • Cytokine Inhibitors
  • Cell-Based Therapies
  • Gene Therapies
  • Small Molecule Drugs
  • Combination Therapies

Indications Covered:

  • Multiple Sclerosis
  • Neuromyelitis Optica
  • Autoimmune Encephalitis
  • Myasthenia Gravis
  • Alzheimer's Disease
  • Parkinson's Disease

Route of Administrations Covered:

  • Intravenous
  • Subcutaneous
  • Oral
  • Intratheca

Technologies Covered:

  • Biologics Development
  • Recombinant DNA Technology
  • Cell Engineering
  • Precision Medicine Platforms

End Users Covered:

  • Hospitals
  • Specialty Clinics
  • Research Institutes
  • Ambulatory Surgical Centers

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Neuroimmune Therapy Market, By Therapy Type

  • 5.1 Monoclonal Antibodies
  • 5.2 Immunomodulators
  • 5.3 Cytokine Inhibitors
  • 5.4 Cell-Based Therapies
  • 5.5 Gene Therapies
  • 5.6 Small Molecule Drugs
  • 5.7 Combination Therapies

6 Global Neuroimmune Therapy Market, By Indication

  • 6.1 Multiple Sclerosis
  • 6.2 Neuromyelitis Optica
  • 6.3 Autoimmune Encephalitis
  • 6.4 Myasthenia Gravis
  • 6.5 Alzheimer's Disease
  • 6.6 Parkinson's Disease

7 Global Neuroimmune Therapy Market, By Route of Administration

  • 7.1 Intravenous
  • 7.2 Subcutaneous
  • 7.3 Oral
  • 7.4 Intrathecal

8 Global Neuroimmune Therapy Market, By Technology

  • 8.1 Biologics Development
  • 8.2 Recombinant DNA Technology
  • 8.3 Cell Engineering
  • 8.4 Precision Medicine Platforms

9 Global Neuroimmune Therapy Market, By End User

  • 9.1 Hospitals
  • 9.2 Specialty Clinics
  • 9.3 Research Institutes
  • 9.4 Ambulatory Surgical Centers

10 Global Neuroimmune Therapy Market, By Distribution Channel

  • 10.1 Hospital Pharmacies
  • 10.2 Retail Pharmacies
  • 10.3 Online Pharmacies

11 Global Neuroimmune Therapy Market, By Geography

  • 11.1 North America
    • 11.1.1 United States
    • 11.1.2 Canada
    • 11.1.3 Mexico
  • 11.2 Europe
    • 11.2.1 United Kingdom
    • 11.2.2 Germany
    • 11.2.3 France
    • 11.2.4 Italy
    • 11.2.5 Spain
    • 11.2.6 Netherlands
    • 11.2.7 Belgium
    • 11.2.8 Sweden
    • 11.2.9 Switzerland
    • 11.2.10 Poland
    • 11.2.11 Rest of Europe
  • 11.3 Asia Pacific
    • 11.3.1 China
    • 11.3.2 Japan
    • 11.3.3 India
    • 11.3.4 South Korea
    • 11.3.5 Australia
    • 11.3.6 Indonesia
    • 11.3.7 Thailand
    • 11.3.8 Malaysia
    • 11.3.9 Singapore
    • 11.3.10 Vietnam
    • 11.3.11 Rest of Asia Pacific
  • 11.4 South America
    • 11.4.1 Brazil
    • 11.4.2 Argentina
    • 11.4.3 Colombia
    • 11.4.4 Chile
    • 11.4.5 Peru
    • 11.4.6 Rest of South America
  • 11.5 Rest of the World (RoW)
    • 11.5.1 Middle East
      • 11.5.1.1 Saudi Arabia
      • 11.5.1.2 United Arab Emirates
      • 11.5.1.3 Qatar
      • 11.5.1.4 Israel
      • 11.5.1.5 Rest of Middle East
    • 11.5.2 Africa
      • 11.5.2.1 South Africa
      • 11.5.2.2 Egypt
      • 11.5.2.3 Morocco
      • 11.5.2.4 Rest of Africa

12 Strategic Market Intelligence

  • 12.1 Industry Value Network and Supply Chain Assessment
  • 12.2 White-Space and Opportunity Mapping
  • 12.3 Product Evolution and Market Life Cycle Analysis
  • 12.4 Channel, Distributor, and Go-to-Market Assessment

13 Industry Developments and Strategic Initiatives

  • 13.1 Mergers and Acquisitions
  • 13.2 Partnerships, Alliances, and Joint Ventures
  • 13.3 New Product Launches and Certifications
  • 13.4 Capacity Expansion and Investments
  • 13.5 Other Strategic Initiatives

14 Company Profiles

  • 14.1 Roche Holding AG
  • 14.2 Novartis AG
  • 14.3 Pfizer Inc.
  • 14.4 Johnson & Johnson
  • 14.5 Bristol-Myers Squibb Company
  • 14.6 Biogen Inc.
  • 14.7 Merck & Co., Inc.
  • 14.8 Eli Lilly and Company
  • 14.9 Sanofi S.A.
  • 14.10 AbbVie Inc.
  • 14.11 GlaxoSmithKline plc
  • 14.12 Amgen Inc.
  • 14.13 UCB S.A.
  • 14.14 Takeda Pharmaceutical Company Limited
  • 14.15 AstraZeneca plc
  • 14.16 Regeneron Pharmaceuticals, Inc.
  • 14.17 Bayer AG
  • 14.18 Teva Pharmaceutical Industries Ltd.

List of Tables

  • Table 1 Global Neuroimmune Therapy Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Neuroimmune Therapy Market Outlook, By Therapy Type (2023-2034) ($MN)
  • Table 3 Global Neuroimmune Therapy Market Outlook, By Monoclonal Antibodies (2023-2034) ($MN)
  • Table 4 Global Neuroimmune Therapy Market Outlook, By Immunomodulators (2023-2034) ($MN)
  • Table 5 Global Neuroimmune Therapy Market Outlook, By Cytokine Inhibitors (2023-2034) ($MN)
  • Table 6 Global Neuroimmune Therapy Market Outlook, By Cell-Based Therapies (2023-2034) ($MN)
  • Table 7 Global Neuroimmune Therapy Market Outlook, By Gene Therapies (2023-2034) ($MN)
  • Table 8 Global Neuroimmune Therapy Market Outlook, By Small Molecule Drugs (2023-2034) ($MN)
  • Table 9 Global Neuroimmune Therapy Market Outlook, By Combination Therapies (2023-2034) ($MN)
  • Table 10 Global Neuroimmune Therapy Market Outlook, By Indication (2023-2034) ($MN)
  • Table 11 Global Neuroimmune Therapy Market Outlook, By Multiple Sclerosis (2023-2034) ($MN)
  • Table 12 Global Neuroimmune Therapy Market Outlook, By Neuromyelitis Optica (2023-2034) ($MN)
  • Table 13 Global Neuroimmune Therapy Market Outlook, By Autoimmune Encephalitis (2023-2034) ($MN)
  • Table 14 Global Neuroimmune Therapy Market Outlook, By Myasthenia Gravis (2023-2034) ($MN)
  • Table 15 Global Neuroimmune Therapy Market Outlook, By Alzheimer's Disease (2023-2034) ($MN)
  • Table 16 Global Neuroimmune Therapy Market Outlook, By Parkinson's Disease (2023-2034) ($MN)
  • Table 17 Global Neuroimmune Therapy Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 18 Global Neuroimmune Therapy Market Outlook, By Intravenous (2023-2034) ($MN)
  • Table 19 Global Neuroimmune Therapy Market Outlook, By Subcutaneous (2023-2034) ($MN)
  • Table 20 Global Neuroimmune Therapy Market Outlook, By Oral (2023-2034) ($MN)
  • Table 21 Global Neuroimmune Therapy Market Outlook, By Intrathecal (2023-2034) ($MN)
  • Table 22 Global Neuroimmune Therapy Market Outlook, By Technology (2023-2034) ($MN)
  • Table 23 Global Neuroimmune Therapy Market Outlook, By Biologics Development (2023-2034) ($MN)
  • Table 24 Global Neuroimmune Therapy Market Outlook, By Recombinant DNA Technology (2023-2034) ($MN)
  • Table 25 Global Neuroimmune Therapy Market Outlook, By Cell Engineering (2023-2034) ($MN)
  • Table 26 Global Neuroimmune Therapy Market Outlook, By Precision Medicine Platforms (2023-2034) ($MN)
  • Table 27 Global Neuroimmune Therapy Market Outlook, By End User (2023-2034) ($MN)
  • Table 28 Global Neuroimmune Therapy Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 29 Global Neuroimmune Therapy Market Outlook, By Specialty Clinics (2023-2034) ($MN)
  • Table 30 Global Neuroimmune Therapy Market Outlook, By Research Institutes (2023-2034) ($MN)
  • Table 31 Global Neuroimmune Therapy Market Outlook, By Ambulatory Surgical Centers (2023-2034) ($MN)
  • Table 32 Global Neuroimmune Therapy Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 33 Global Neuroimmune Therapy Market Outlook, By Hospital Pharmacies (2023-2034) ($MN)
  • Table 34 Global Neuroimmune Therapy Market Outlook, By Retail Pharmacies (2023-2034) ($MN)
  • Table 35 Global Neuroimmune Therapy Market Outlook, By Online Pharmacies (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.